SCHEMBL23198535

SCHEMBL23198535

CCOC(=O)c1cc(Cl)c2cnccc2n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
CYP1A2 P05177 1/20 0.44
KDM5A P29375 1/20 0.43
KDM5B Q9UGL1 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
CASP1 P29466 1/20 0.41
KDM4E B2RXH2 2/20 0.41
BRAF P15056 1/20 0.41
EIF2AK3 Q9NZJ5 1/20 0.41
CTSL P07711 1/20 0.41
CTSB P07858 1/20 0.41
HPGD P15428 1/20 0.41
GABRA2 P47869 1/20 0.41
GABRB2 P47870 1/20 0.41
ELANE P08246 2/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31254231 1.00 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2CYP1A2KDM5AKDM5B
SCHEMBL23202573 0.90 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2CYP1A2KDM5AKDM5B
SCHEMBL30474276 0.90 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2CYP1A2KDM5AKDM5B
SCHEMBL163381 0.82 SMN1; SMN2 (0.53) ALDH1A1SMN1; SMN2CYP1A2KMT2AMEN1
SCHEMBL9729781 0.81 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2CYP1A2L3MBTL1KMT2A
SCHEMBL212240 0.80 CYP1A2 (0.45) ALDH1A1SMN1; SMN2CYP1A2KDM5AKDM5B
SCHEMBL31373449 0.80 CYP1A2 (0.45) ALDH1A1SMN1; SMN2CYP1A2KDM5AKDM5B
SCHEMBL5101784 0.80 GPR35 (0.49) KDM4E
SCHEMBL2652933 0.78 CTSL (0.61) ALDH1A1SMN1; SMN2KMT2AMEN1KDM4E
SCHEMBL31410807 0.77 ADORA3 (0.47) ALDH1A1SMN1; SMN2KMT2AMEN1ELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026763-A1 EGFR INHIBITORS AND METHODS OF USE THEREOF Allorion Therapeutics Inc 2025-01-23 US disclosed
US-20220402917-A1 COMPOUND AS SMALL MOLECULE INHIBITOR PD-1/PD-L1 AND APPLICATION THEREOF MEDSHINE DISCOVERY INC. (CN) 2022-12-22 US disclosed
EP-4043461-A1 COMPOUND AS SMALL MOLECULE INHIBITOR PD-1/PD-L1 AND APPLICATION THEREOF Medshine Discovery Inc. (CN) 2022-08-17 EP disclosed
WO-2021063404-A1 COMPOUND AS SMALL MOLECULE INHIBITOR PD-1/PD-L1 AND APPLICATION THEREOF 南京明德新药研发有限公司 2021-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220402917-A1 COMPOUND AS SMALL MOLECULE INHIBITOR PD-1/PD-L1 AND APPLICATION THEREOF CD274, PDCD1, PDCD1LG2 ALDH1A1 138/4885SMN1; SMN2 4440/4885CYP1A2 3388/4885
US-20250026763-A1 EGFR INHIBITORS AND METHODS OF USE THEREOF EGFR, ERBB3, ERBB2 ALDH1A1 4536/4885SMN1; SMN2 4856/4885CYP1A2 4214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.